TABLE 2

Mean relative distribution (percentage) of [¹⁴C]muraglitazar metabolites produced by human cDNA-expressed P450 enzymes

Expressed P450	Mean Relative Distribution (n = 2)^a
Expressed P450		Parent	M10	M11	M14	M15	Total^b
	%
HLM (no NADPH)	94.77	0.39	0.06	0.12	0.25	95.59
HLM	85.59	3.13	0.78	1.27	1.86	92.63
1A2	90.21	0.54	0.23	0.06	0.30	91.64
2A6	89.32	0.49	0.08	0.08	0.26	90.23
2B6	90.25	0.51	0.00	0.00	0.00	90.76
2C8	89.42	1.12	0.07	0.22	1.87	92.70
2C9	90.64	3.03	0.13	0.05	0.32	94.17
2C18	91.75	0.50	0.06	0.12	0.25	92.68
2C19	68.40	6.33	18.24	0.13	0.26	93.36
2D6	82.90	1.11	0.41	0.07	0.76	85.25^c
2E1	93.84	0.31	0.08	0.08	0.16	94.47
3A4	81.39	2.56	0.17	3.82	0.67	88.61^d
3A5	92.35	0.57	0.09	0.33	0.41	93.75

↵ a Metabolites were selected based on those predominant in vivo in human metabolites (Zhang et al., 2006). The variability between two runs was less than 15%.
↵ b Total was less than 100% because low levels of degradation products eluted between 17 and 22 min on HPLC were observed in all incubations including no-NADPH control incubations.
↵ c Less than 90% because M9, M16, and other radioactive peaks were prominent peaks in the incubations.
↵ d Less than 90% because M1, M9, M16, and other radioactive peaks were significant peaks in the incubations.